Skip to main content
Premium Trial:

Request an Annual Quote

David Onions, Paul Grint, Illumina, CombiMatrix

Premium

People in the News

David Onions has been promoted to chief medical officer of Invitrogen, a new position, the company said last week. He used to be chief scientific officer for BioReliance, a company Invitrogen acquired in 2004. As CMO, Onions will be responsible for guiding Invitrogen's scientific efforts as it moves into areas more closely associated with medical research and closer to patients. He is also a personal chair in veterinary molecular virology at the University of Glasgow. Onions holds a PhD from the University of Cambridge and a BVSc from Bristol University.


Paul Grint has become chief medical officer and head of development of Kalypsys, the San Diego-based company said last week. Prior to joining Kalypsys, he was senior vice president and chief medical officer of Zephyr Sciences. He is also a member of the board of directors of Illumina. Grint holds a medical degree from the University of London, St. Bartholomew's Hospital Medical College.

 

New Product Watch

Illumina last week launched two Sentrix Mouse Expression BeadChips, which the company claims enable multi-sample whole-genome or RefSeq-based expression profiling of multi-mouse samples.

According to Illumina, the Sentrix Mouse-6 BeadChip is designed to analyze six separate mouse RNA samples on one chip, interrogating in each sample approximately 48,000 sequences from the mouse transcriptome.

The Sentrix MouseRef-8 BeadChip can query eight samples in parallel against approximately 24,000 sequences derived from transcripts represented in the consensus RefSeq database.

Illumina said that it plans to release a genome-wide expression array for the rat genome before the end of the year.


CombiMatrix last week launched its CustomArray 4X2K. The company claims the product contains four independent 2,000-feature microarrays on a single CustomArray.

Michael Tognotti, CombiMatrix's vice president of sales and marketing, said that the chip is "ideally suited" for customers that "desire low-cost arrays and do not need a large number of features per array."

The 4X2K is priced starting at $99 per 2,000-feature microarray. It will be marketed to the pharmaceutical, biotechnology, diagnostic, academic, and government sectors, CombiMatrix said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.